Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICLA: PD-1 with Neoadjuvant Chemoradiotherapy for Esophagogastric Junction Adenocarcinoma
NCT05505461Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in adenocarcinoma of the esophagogastric junction (AEG), sponsored by Peking University People's Hospital. Primary endpoint: Pathological Complete Response Rate at 6 months. Planned start Jan 2023; status: not yet recruiting.
02
Conditions
adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT05505461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505461.